CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab), a treatment for patients with PNH, will be presented at the 2007 American Society of Hematology Meeting, December 8 - 11 in Atlanta.
The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The session will open at 10:30 a.m. and poster presentations will be held from 5:00 to 7:00 p.m. for each abstract. Additional information can be accessed through the links provided below.
http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438
The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.
http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302
CONTACT: Irving Adler, Sr. Director of Corporate Communications at Alexion
Pharmaceuticals, Inc., +1-203-272-8210; Media, Mark Marmur of Makovsky &
Company, +1-212-508-9670, or Investors, Rhonda Chiger of Rx Communications,
+1-917-322-2569, both for Alexion Pharmaceuticals, Inc.
